[Behavior of plasma renin activity (PRA) after administration of a calcium antagonist].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to D Cucinotta.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The hepatic tolerability of phthalazine-(2,2-b)-phthalazin-5,12-(7H,14H)-dione (diftalone--administered at the dosage of 750 mg/day p.o. for a mean period of 23 days--has been studied in 40 patients by means of: total plasma protein, albumin, fibrinogen, serum glutamin-oxalacetic transaminase, serum glutamic-pyruvic transaminase, lactic dehydrogenase, creatine phosphokinase, alkaline phosphatase, glycemic curve after glucagon and plasmatic elimination of bromosulphalein. A statistically but not clinically significant increase of the SGPT level is the only change observed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The authors studied the effectiveness and biological tolerability of Tiadenol [Bis-(hydroxy-2-ethylthyo)-1,10-decano] against clofibrate, in a group of 38 hyperlipaemic (volunteers) subjects, with or without atherosclerotic disease. The results showed that the new hypolipidaemic drug has a great effect on cholesterolemia and trigliceridaemia, as does clofibrate. The statistic examination confirmed the results. This research didn't show any side-effects of the drug, which has a very good biological tolerability.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.